Jonker M, Neuhaus P, Zurcher C, Fucello A, Goldstein G
Transplantation. 1985 Mar;39(3):247-53. doi: 10.1097/00007890-198503000-00006.
A mixture of OKT4+4A monoclonal antibodies (reactive with T4 cells) was tested for its immunosuppressive potential in rhesus monkeys receiving a kidney allograft. The kidney transplant model used in this study was designed to mimic the clinical situation. Therefore, all animals received a low dose of azathioprine and prednisolone, and the effectiveness of monoclonal antibody treatment was assessed in nontransfused and transfused recipients. The treatment very effectively suppressed acute graft rejection in untransfused recipients. In transfused recipients, which show an improved graft survival, no additional favorable effect of OKT4 + 4A treatment was seen when this treatment was given at the time of transplantation. It is possible that transfused recipients that reject their kidney in an acute fashion do not benefit from the OKT4 + 4A treatment because they have generated primed effector cells that belong to a T4-negative subpopulation or a T4-positive subpopulation with high affinity for donor cells. When the OKT4 + 4A treatment was given at the time of graft rejection in transfused recipients, thus treating chronic rather than acute rejection, a modest improvement in graft survival was observed. It seems, therefore, that anti-T4 antibodies will be of limited value for clinical transplantation and should be used in combination with other immunosuppressive drugs.
检测了OKT4 + 4A单克隆抗体混合物（与T4细胞反应）在接受肾移植的恒河猴中的免疫抑制潜力。本研究中使用的肾移植模型旨在模拟临床情况。因此，所有动物均接受低剂量的硫唑嘌呤和泼尼松龙，并在未输血和输血的受体中评估单克隆抗体治疗的有效性。该治疗非常有效地抑制了未输血受体中的急性移植物排斥反应。在移植物存活有所改善的输血受体中，在移植时给予OKT4 + 4A治疗未观察到额外的有益效果。有可能以急性方式排斥其肾脏的输血受体无法从OKT4 + 4A治疗中获益，因为它们已经产生了属于T4阴性亚群或对供体细胞具有高亲和力的T4阳性亚群的致敏效应细胞。当在输血受体的移植物排斥时给予OKT4 + 4A治疗，从而治疗慢性而非急性排斥反应时，观察到移植物存活有适度改善。因此，抗T4抗体对于临床移植的价值似乎有限，应与其他免疫抑制药物联合使用。
